Early clinical studies to explore candidate biomarkers in targeted cancer therapies
PhD ceremony: Ms. C.N.A.M. Oldenhuis, 12.45 uur, Academiegebouw, Broerstraat 5, Groningen
Dissertation: Early clinical studies to explore candidate biomarkers in targeted cancer therapies
Promotor(s): prof. J.A. Gietema, prof. E.G.E. de Vries, prof. S. de Jong
Faculty: Medical Sciences
Currently, much information is becoming available from tumor cell biology research, opening opportunities for the development of specifically tumor targeting agents. In this thesis we studied the safety, tolerability and pharmacokinetics of two novel targeted agents in phase 1 studies. An oral angiogenesis inhibitor and the apoptosis inducing agonistic antibody mapatumumab both appeared safe in combination with chemotherapy. No pharmacokinetic interactions were seen. Further studies on this combination are therefore warranted.
| Last modified: | 13 March 2020 01.02 a.m. |
More news
-
24 March 2025
UG 28th in World's Most International Universities 2025 rankings
The University of Groningen has been ranked 28th in the World's Most International Universities 2025 by Times Higher Education. With this, the UG leaves behind institutions such as MIT and Harvard. The 28th place marks an increase of five places: in...
-
05 March 2025
Women in Science
The UG celebrates International Women’s Day with a special photo series: Women in Science.
-
28 February 2025
Vici grants for two UG/UMCG scientists
The Dutch Research Council (NWO) has awarded Vici grants, worth up to €1.5 million each, to Merel Keijzer and Charalampos Tsoumpas This will enable the researchers to develop an innovative line of research and set up their own research group for...